David Jnr was only 14 months old when he contracted pneumococcal meningitis. After being rushed to...
Meningococcal disease is serious and can sometimes cause death or permanent disability such as deafness or disfigurement.
There are a number of vaccines available which protect against different strains of meningococcal disease. They are not publicly funded under the National Immunisation Schedule (apart from some people at high risk i.e. without spleens), but are available for private purchase through your GP.
There are currently no vaccines available in New Zealand that protect against meningococcal B. The MeNZBTM vaccine was introduced and offered to all babies, children and teenagers in New Zealand from 2004 to 2008 against an epidemic of a specific strain of the meningococcal B disease. The MeNZB™ vaccine is no longer on New Zealand’s Immunisation Schedule. The rates of disease caused by this particular strain fell to a level where experts advised that offering it routinely was no longer necessary.
Today In New Zealand, the two main types of meningococcal vaccines available are;
This protects against groups A, C, Y and W135 and is available for persons over the age of two. Initial immunisation involves one vaccine dose which lasts approximately 3 years – This period may be shorter for young children and longer for some people.
This is free and recommended for;
Adults before or after a splenectomy
Children before or after a splenectomy, or suffering from functional asplenia (where the spleen doesn’t function at all, or only partly)
This vaccine is also recommended, but not funded for;
Young adults entering hostel-type accommodation, especially for their first year (note: meningococcal C conjugate vaccine can also be used)
People with sickle cell anaemia
People with terminal complement deficiencies
People with HIV infection
Microbiologists and laboratory workers who may be exposed to meningococcal bacteria isolates
Travellers to regions where this disease is prevalent, especially anyone taking part in the Hajj, or visiting sub-Saharan Africa (known as the ‘Meningitis Belt’)
This vaccine provides protection against group C meningococcal bacteria.
This can be used to protect children under the age of 24months. It is administered via one dose for children over 12months of age, and for adults, or via three doses for infants who are less than 12months of age. Each vaccine has a minimum age for first dose, and subsequent dosages. The duration of immunity from the conjugate vaccines is currently unknown. A booster dose following the initial course in infants may be needed to sustain longer-term immunity. Speak to your GP for further information.
Are there possible reactions to the vaccine?
Local reactions to the polysaccharide vaccine are usually mild, and can include redness, and swelling and pain at the injection site and the local lymph glands. Fever and chills occur in approximately two percent of young children. Common reactions to the conjugate vaccine can include pain, redness and swelling at the site of injection, fever, irritability, decreased appetite and headaches. Significant adverse reactions are rare.
For more advice on vaccines and their availability, talk to your family doctor, call the free Immunisation Advisory Centre helpline 0800 IMMUNE (0800 466 863), or see the Immunisation Handbook (2011).
Current vaccination information sourced from the Ministry of Health website
Disclaimer - The Meningitis Foundation Aotearoa New Zealand promotes the prevention, control and awareness of meningitis. It is not a professional medical authority. The text on this website provides general information about meningitis and septicaemia, not medical advice. It is not intended for use in the diagnosis or treatment of these diseases. Please consult your doctor to discuss the information or if you are concerned someone may be ill.
We need your help in reducing and preventing meningitis. Your support will assist the Foundation’s work in the fight against this disease.